- Home
- VRTX vs BMY Comparison
VRTX vs BMY Comparison
Compare VRTX & BMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRTX
- BMY
- Stock Information
- Founded
- VRTX 1989
- BMY 1887
- Country
- VRTX United States
- BMY United States
- Employees
- VRTX N/A
- BMY N/A
- Industry
- VRTX EDP Services
- BMY Biotechnology: Pharmaceutical Preparations
- Sector
- VRTX Technology
- BMY Health Care
- Exchange
- VRTX Nasdaq
- BMY Nasdaq
- Market Cap
- VRTX 115.6B
- BMY 120.5B
- IPO Year
- VRTX 1991
- BMY N/A
- Fundamental
- Price
- VRTX $446.75
- BMY $46.87
- Analyst Decision
- VRTX Buy
- BMY Hold
- Analyst Count
- VRTX 26
- BMY 16
- Target Price
- VRTX $512.54
- BMY $58.93
- AVG Volume (30 Days)
- VRTX 2.1M
- BMY 16.5M
- Earning Date
- VRTX 05-05-2025
- BMY 04-24-2025
- Dividend Yield
- VRTX N/A
- BMY 5.29%
- EPS Growth
- VRTX N/A
- BMY N/A
- EPS
- VRTX N/A
- BMY 2.67
- Revenue
- VRTX $11,099,700,000.00
- BMY $47,636,000,000.00
- Revenue This Year
- VRTX $10.36
- BMY N/A
- Revenue Next Year
- VRTX $10.61
- BMY N/A
- P/E Ratio
- VRTX N/A
- BMY $17.54
- Revenue Growth
- VRTX 8.98
- BMY 4.62
- 52 Week Low
- VRTX $377.85
- BMY $39.35
- 52 Week High
- VRTX $519.88
- BMY $63.33
- Technical
- Relative Strength Index (RSI)
- VRTX 44.94
- BMY 43.23
- Support Level
- VRTX $427.43
- BMY $46.47
- Resistance Level
- VRTX $448.00
- BMY $48.26
- Average True Range (ATR)
- VRTX 11.02
- BMY 1.17
- MACD
- VRTX 0.83
- BMY 0.32
- Stochastic Oscillator
- VRTX 88.27
- BMY 69.68
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
About BMY Bristol-Myers Squibb Company
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.